Skip to main content

Table 1 Cases characteristics of SSIBs associated with GLP-1RA in the FAERS database

From: Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database

Categories

Semaglutide N (%)

Liraglutide N (%)

Dulaglutide N (%)

Exenatide N (%)

Albiglutide N (%)

Total N (%)

Reports of SSIBs

57

74

51

20

2

204

Report year

 2018

2 (3.51)

16 (21.62)

12 (23.53)

4 (20.00)

1 (50.00)

35 (17.16)

 2019

4 (7.02)

11 (14.86)

7 (13.73)

7 (35.00)

0

29 (14.22)

 2020

8 (14.04)

19 (25.68)

10 (19.61)

4 (20.00)

1 (50.00)

42 (20.59)

 2021

16 (28.07)

12 (16.22)

8 (15.69)

2 (10.00)

0

38 (18.63)

 2022

27 (47.37)

16 (21.62)

14 (27.45)

3 (15.00)

0

60 (29.41)

Reporter a

 Healthcare professional

30 (52.63)

53 (71.62)

19 (37.25)

9 (45.00)

1 (50.00)

112 (54.90)

 Nonhealthcare professional

26 (45.61)

21 (28.38)

31 (60.78)

6 (30.00)

1 (50.00)

85 (41.67)

 Unknown or missing

1 (1.75)

0

1 (1.96)

5 (25.00)

0

7 (3.43)

Sex

 Male

18 (31.58)

20 (27.03)

19 (37.25)

9 (45.00)

1 (50.00)

67 (32.84)

 Female

38 (66.67)

52 (70.27)

29 (56.86)

11 (55.00)

1 (50.00)

131 (64.22)

 Unknown or missing

1 (1.75)

2 (2.70)

3 (5.88)

0

0

6 (2.94)

Age category, years

 Juvenile (< 18)

0

0

0

3 (15.00)

0

3 (1.47)

 Adult (18–65)

28 (49.12)

43 (58.11)

24 (47.06)

7 (35.00)

0

102 (50.00)

 Seniors (> 65)

1 (1.75)

7 (9.46)

10 (19.61)

2 (10.00)

0

20 (9.80)

 Unknown or missing

28 (49.12)

24 (32.43)

17 (33.33)

8 (40.00)

2 (100.00)

79 (38.73)

 Median (IQR)

43 (35–52)

47 (36–57)

55 (46–67)

40 (25–54)

/

/

Indication

 Type 2 diabetes mellitus

13 (22.81)

14 (18.92)

30 (58.82)

13 (65.00)

1 (50.00)

71 (34.80)

 Weight loss

15 (26.32)

15 (20.27)

0

0

0

30 (14.71)

 Others

1 (1.75)

4 (5.41)

0

3 (15.00)

0

8 (3.92)

 Unknown or missing

28 (49.12)

41 (55.41)

21 (41.18)

4 (20.00)

1 (50.00)

95 (46.57)

Outcomesb

 Death

1 (1.75)

17 (22.97)

3 (5.88)

1 (5.00)

0

22 (10.78)

 Life-threatening

6 (10.53)

6 (8.11)

3 (5.88)

5 (25.00)

0

20 (9.80)

 Hospitalization

8 (14.04)

20 (27.03)

19 (37.25)

7 (35.00)

0

54 (26.47)

 Disability

2 (3.51)

1 (1.35)

2 (3.92)

1 (5.00)

0

6 (2.94)

 Other serious illness

52 (91.23)

55 (74.32)

37 (72.55)

12 (60.00)

2 (100)

158 (77.45)

  1. IQR interquartile range, SSIBs Suicidal and Self-Injurious Behaviors, GLP-1RAs GLP-1 receptor agonists
  2. aHealthcare professionals including reporters such as physicians and pharmacists; nonhealthcare professionals including reporters such as consumer and lawyer
  3. bSince a case may experience different clinical outcomes during drug therapy, it is reasonable that the sum percentage of the outcome under this item may exceed 100%